Vertex Pharmaceuticals (VRTX) Operating Leases (2018 - 2026)

Vertex Pharmaceuticals' Operating Leases history runs 9 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• In Q1 2026, Operating Leases rose 29.19% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (up 29.19% YoY), while the FY2025 annual figure was $1.8 billion, up 19.56% from the prior year.
• Operating Leases was $2.0 billion for Q1 2026 at Vertex Pharmaceuticals, up from $1.8 billion in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.0 billion in Q1 2026 to a low of $348.6 million in Q4 2023.
• Historically, Operating Leases has averaged $929.6 million across 5 years, with a median of $428.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Leases declined 18.57% in 2023, then soared 348.34% in 2024.
• A 5-year view of Operating Leases shows it stood at $428.1 million in 2022, then retreated by 18.57% to $348.6 million in 2023, then soared by 343.03% to $1.5 billion in 2024, then advanced by 19.56% to $1.8 billion in 2025, then increased by 7.58% to $2.0 billion in 2026.
• The last three Operating Leases figures came in at $2.0 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.